The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

Glioblastoma multiforme (GBM) remains one of the most devastating tumors, and patients have a median survival of 15 months despite aggressive local and systemic therapy, including maximal surgical resection, radiation therapy, and concomitant and adjuvant temozolomide. The purpose of antineoplastic...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Poulsen, Hans Skovgaard, Urup, Thomas, Michaelsen, Signe Regner, Staberg, Mikkel, Villingshøj, Mette, Lassen, Ulrik
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2014
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186574/
https://ncbi.nlm.nih.gov/pubmed/25298738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S39306
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak